We are live on ! Find out more
VSTM icon

Verastem

109 hedge funds and large institutions have $218M invested in Verastem in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 20 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 20

107% more call options, than puts

Call options by funds: $937K | Put options by funds: $452K

65% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 17

11.64% more ownership

Funds ownership: 84.05%95.69% (+12%)

10% more funds holding

Funds holding: 99109 (+10)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

16% less capital invested

Capital invested by funds: $261M → $218M (-$42.7M)

Holders
109
Holders Change
+10
Holders Change %
+10.1%
% of All Funds
1.44%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
28
Increased
47
Reduced
20
Closed
17
Calls
$937K
Puts
$452K
Net Calls
+$485K
Net Calls Change
+$194K
Name Holding Trade Value Shares
Change
Change in
Stake
GBT
126
Grove Bank & Trust
Florida
-$48 -8 Closed

VSTM Hedge Fund Activity: Q2 2025 in Review

109 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Verastem (VSTM) for Q2 2025, worth a combined $218M — down 16% from $261M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VSTM positions and 17 closed out — a net gain of 11 holders — while 47 added to existing stakes and 20 trimmed.

The largest buyer was J. Goldman & Co, adding an estimated $14.3M. The largest seller was OrbiMed, exiting entirely with an estimated $17.3M sold.

  • 109 institutional investors held Verastem (VSTM) as of Q2 2025, up from 99 in Q1 2025.
  • Funds reported $218M of Verastem stock for Q2 2025, down 16% quarter-over-quarter.
  • 28 funds opened new Verastem positions in Q2 2025 and 17 closed out, a net change of +11 holders.
  • The largest Verastem buyer in Q2 2025 was J. Goldman & Co, an estimated $14.3M added.
  • The largest Verastem seller in Q2 2025 was OrbiMed, an estimated $17.3M sold.

Based on aggregated 13F filings for Q2 2025.